Bio-link Australia Pty. Ltd.

Bio-Link News

Please find below a list of recent news and press releases from Bio-Link.

Christos Papadimitriou & Lilly Bojarski selected for 2018 Bridge Program

Bio-Link’s Christos Papadimitriou and Lilly Bojarski have been selected for the MTPCOnnect Bridge Program 2018, which offers strategic professional training to advance skills necessary to boost the commercialisation of Australian innovative research and biotechnologies. Bio-Link is pleased to be represented for a second year, following the inauguration of the initiative in 2017. Learn more about the program here.

4th January 2018 – Bio-Link Engaged by FivepHusion

Bio-Link has been engaged by FivepHusion Pty Ltd to assist with commercialisation of Deflexifol.  FivepHusion has developed Deflexifol, an innovative formulation of 5-FU and leucovorin, as a replacement for the current standard of care in solid tumour indications. A Phase II clinical in colorectal carcinoma trial is planned. To learn more about this opportunity, please click here.

19th October 2017 – Heptares Therapeutics engages Bio-Link to identify clinical collaborators

Heptares Therapeutics, a clinical-stage company creating transformative medicines targeting G protein-coupled receptors (GPCRs) has engaged Bio-Link to identify clinical collaborators for clinical studies investigating the role of individual GPCRs in human health and there role in human pathogenesis.

17th July 2017 – Bio-Link’s Dr Lieven Huang Attending ‘Business of Regenerative Medicine’ in Toronto This Week

After winning a CCRM Australia grant, Bio-Link’s Dr Lieven Huang is attending the 2017 edition of ‘Business of Regenerative Medicine’ in Toronto, which is focused on the latest in commercialising regenerative medicine and stem cell therapies. The event is co-hosted by the Centre for Commercialization of Regenerative Medicine (CCRM) and the Rotman School of Management. More information about the event here.

8th May 2017 – Bio-Link Survey: Antibody(-like) Therapeutics in Australia

BIOLINK_logov2



Bio-Link is engaged by a client to scout for Australian therapeutics programs with antibodies and antibody-like drugs. All stages of development are considered, both within academia (e.g. Garvan Institute’s Centre for Targeted Therapies) and industry (e.g. CSL). The scouting results are likely to be shared with the global pharma industry, which might boost commercial R&D activities in Australia. Names of research groups or companies can be submitted below.
Thanks for your input!

Organisation Details

Name of Research Groups and/or Companies:
Technology/Program Specifics:




Bio-Link Australia Pty Ltd , www.bio-link.com
Suite 6/98 Glebe Point Road, Glebe, New South Wales, 2037
Level 2, Birdwood Offices, 19 Prospect Street, Box Hill, Victoria, 3128

BIOLINK_logov2

23rd May 2017 – Bio-Link Engaged by Kunovus Technologies

Bio-Link has been engaged by Kunovus Technologies to facilitate partnering of KT009, a preclinical, intra-intervertebral disk-administered regenerative biological therapy for the treatment of degenerative disk disease and chronic back pain. Kunovus Technologies has compelling preclinical data supporting KT009-mediated disk regeneration and subsequent reduction in pain. KT009 is poised to enter GMP manufacturing and formal preclinical assessment prior to clinical evaluation.

To learn more about this partnering opportunity, please click here.

Kunovus Technologies

16th May 2017 – Bio-Link Engaged by Actinogen Medical

Bio-Link has been engaged by Actinogen Medical to facilitate partnering of Xanamem™,a phase II, first-in-class, orally active, brain penetrant, potent and selective 11β-HSD1 inhibitor; designed to reduce regeneration of cortisol within the brain. Today, Actinogen Medical has announced treatment of the first patient in a global phase II clinical study investigating Xanamem™ for the treatment of Alzheimer’s disease.

To learn more about this partnering opportunity, please click here.

Actinogen

2nd May 2017 – Bio-Link Engaged by GenoFAB

Bio-Link has been engaged by GenoFAB to assist with the commercialisation of iVectors™, a new generation of intelligently designed, high-performance, custom protein expression vectors that have been optimized for upstream and downstream processing to rescue difficult-to-manufacture proteins.

To learn more about this partnering opportunity, please click here.

Older News